Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit.~* Have HbA1c between ≥7.0% and ≤10.5%.~* Have a stable weight (± 5%) for at least 3 months before screening.~* Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²) at screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus.~* Have had chronic or acute pancreatitis any time prior to study entry.~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m² \[for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\]~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).